trending Market Intelligence /marketintelligence/en/news-insights/trending/eKqLcWSLQ3S0uh8rHK88AA2 content esgSubNav
In This List

Dechra Pharmaceuticals adds director

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Dechra Pharmaceuticals adds director

Dechra Pharmaceuticals PLC appointed Lisa Bright to the board as a nonexecutive director, effective Feb. 1, 2019.

Bright serves on the board of Ascendis Pharma A/S and has been president, international, at Intercept Pharmaceuticals Inc. since July 2016. She was also previously a vice president at GlaxoSmithKline PLC and Gilead Sciences Inc.

Northwich, U.K.-based Dechra Pharmaceuticals develops veterinary pharmaceuticals and related products for veterinarians worldwide.